A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
NCT02996110 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 182
Last updated 2022-12-19
Summary
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Conditions
Interventions
- BIOLOGICAL
-
Specified Dose on Specified Days
- BIOLOGICAL
-
Specified Dose on Specified Days
- BIOLOGICAL
-
Specified Dose on Specified Days
- DRUG
-
BMS-986205
Specified Dose on Specified Days
- DRUG
-
BMS-813160
Specified Dose on Specified Days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-02-02
- Primary Completion
- 2021-11-23
- Completion
- 2021-11-23
- FDA Drug
- Yes
Countries
- United States
- Australia
- Austria
- Canada
- Israel
- Italy
Study Locations
More Related Trials
-
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03749018 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT01968109 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04080804 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
NCT03465592 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
NCT04981509 ·Status: RECRUITING ·Phase: PHASE2
-
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT06029270 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
NCT02857426 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
NCT02332980 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
NCT04205409 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT03075553 ·Status: TERMINATED ·Phase: PHASE2
-
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT02978625 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
NCT03024437 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT04735978 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
NCT03050060 ·Status: TERMINATED ·Phase: PHASE2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
NCT03198026 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
NCT02581631 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT03015896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
NCT02910063 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
NCT03033914 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
NCT02576990 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
NCT04761198 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
NCT03173950 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865 ·Status: COMPLETED ·Phase: PHASE2
-
Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003110 ·Status: COMPLETED ·Phase: PHASE2